Stallergenes Greer

Headquartered in London, Stallergenes Greer plc is a global biopharmaceutical company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services.

Formed by the merger in 2015 of the two companies that make up its name - the former based in France, the latter in the US - Stallergenes Greer has centres in 29 countries and facilities in both Europe and the USA, where it has recently established a new central office in Cambridge, Massachusetts.